Zhao, Mingye; Jiang, Yunlin; Shao, Taihang; Tang, Wenxi - 2025
Objectives To conduct pooled estimates and comparative evaluations of safety and efficacy, alongside cost-effectiveness …-BEV had the greatest PFS and OS survival benefit, followed by fruquintinib and REDo. Cost-effectiveness analysis favored BSC … the most cost-effective among targeted therapies. For cost-effectiveness against BSC, the price reductions of TAS-102 …